RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+13.86%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.94B
AUM Growth
+$5.94B
(-0.87%)
Cap. Flow
-$357M
Cap. Flow
% of AUM
-6.02%
Top 10 Holdings %
Top 10 Hldgs %
66.2%
Holding
90
New
5
Increased
9
Reduced
10
Closed
27
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$111M |
| 2 |
Taysha Gene Therapies
TSHA
|
$29.3M |
| 3 |
Avidity Biosciences
RNA
|
$27.4M |
| 4 |
HNGE
Hinge Health, Inc.
HNGE
|
$15.5M |
| 5 |
Tyra Biosciences
TYRA
|
$14.9M |
Top Sells
| 1 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$81.2M |
| 2 |
Apogee Therapeutics
APGE
|
$58.6M |
| 3 |
Zai Lab
ZLAB
|
$46.8M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
$45.6M |
| 5 |
UroGen Pharma
URGN
|
$35.5M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.77B | 29.9% | 10,281,496 | – | – |
|
2
Vaxcyte
PCVX
$4B
| $389M | 6.55% | 11,965,991 -223,158 | -2% | -$7.25M |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $351M | 5.92% | 5,561,359 -523,053 | -9% | -$33.1M |
|
4
Janux Therapeutics
JANX
$1.37B
| $258M | 4.35% | 11,189,693 | – | – |
|
|
5
Avidity Biosciences
RNA
$5.99B
| $206M | 3.48% | 7,266,031 +965,623 | +15% | +$27.4M |
|
6
Arcellx
ACLX
$3.85B
| $200M | 3.37% | 3,036,527 | – | – |
|
7
89bio
ETNB
$1.34B
| $195M | 3.29% | 19,889,683 | – | – |
|
8
ARS Pharmaceuticals
SPRY
$1.15B
| $190M | 3.19% | 10,860,977 | – | – |
|
9
NewAmsterdam Pharma
NAMS
$2.71B
| $184M | 3.09% | 10,138,938 | – | – |
|
|
SION
10
Sionna Therapeutics, Inc. Common Stock
SION
$1.09B
| $181M | 3.05% | 10,445,322 | – | – |
|
|
11
Cidara Therapeutics
CDTX
$1.66B
| $164M | 2.76% | 3,365,523 +2,272,727 | +208% | +$111M |
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $130M | 2.19% | 9,902,633 +993,542 | +11% | +$13M |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $122M | 2.06% | 4,178,823 | – | – |
|
14
Wave Life Sciences
WVE
$1.53B
| $118M | 1.99% | 18,202,009 | – | – |
|
|
15
Tyra Biosciences
TYRA
$675M
| $117M | 1.97% | 12,198,625 +1,561,335 | +15% | +$14.9M |
|
16
GH Research
GHRS
$837M
| $93.6M | 1.58% | 7,676,697 +732,049 | +11% | +$8.92M |
|
17
Dyne Therapeutics
DYN
$1.92B
| $92.5M | 1.56% | 9,714,392 | – | – |
|
18
Geron
GERN
$893M
| $85.1M | 1.43% | 60,379,366 | – | – |
|
19
Disc Medicine
IRON
$2.07B
| $83.5M | 1.41% | 1,577,106 | – | – |
|
20
Mineralys Therapeutics
MLYS
$1.03B
| $83.2M | 1.4% | 6,147,280 | – | – |
|
|
SEPN
21
Septerna, Inc. Common Stock
SEPN
$539M
| $73.9M | 1.25% | 6,995,858 | – | – |
|
22
Fulcrum Therapeutics
FULC
$351M
| $70.4M | 1.19% | 10,229,099 | – | – |
|
|
BCAX
23
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $64.6M | 1.09% | 6,955,993 | – | – |
|
24
Vor Biopharma
VOR
$250M
| $64.2M | 1.08% | 39,646,039 | – | – |
|
|
25
Taysha Gene Therapies
TSHA
$797M
| $54.4M | 0.92% | 23,555,648 +12,683,145 | +117% | +$29.3M |
|